Faecal calprotectin testing in patients suspected of inflammatory bowel disease (IBD) presenting to primary care
Kessels, S, Mittal, R, Morona, J, Schubert, C, Newton, S
Record ID 32018000648
English
Original Title:
Application 1353.1
Authors' results and conclusions:
On the basis of the evidence profile, it is suggested that, relative to specialist referral and endoscopy and biopsy, faecal calprotectin (FC) testing has superior safety and non-inferior effectiveness. Non-inferior effectiveness comes with uncertainty, and will depend on the actual false negative rate of FC testing in Australian primary care and the decision making by general practitioners (GPs) (the uptake of FC testing by GPs and how the FC result influences referral behaviour by GPs in Australia). However, the avoidance of unnecessary referrals to specialists would be of particular benefit to rural and remote patients, as it would mean that the patient would not need to travel to a specialist centre.
Details
Project Status:
Completed
URL for project:
https://www.msac.gov.au/applications/1353-1
Year Published:
2019
URL for published report:
https://www.msac.gov.au/applications/1353-1
English language abstract:
An English language summary is available
Publication Type:
Other
Country:
Australia
MeSH Terms
- Inflammatory Bowel Diseases
- Biomarkers
- Endoscopy, Gastrointestinal
- Feces
- Unnecessary Procedures
- Leukocyte L1 Antigen Complex
Keywords
- faecal calprotectin testing
Contact
Organisation Name:
Adelaide Health Technology Assessment
Contact Address:
School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
ahta@adelaide.edu.au
Contact Email:
ahta@adelaide.edu.au
Copyright:
<p>Adelaide Health Technology Assessment (AHTA) on behalf of NICS</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.